Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler's pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape. Prescription & OTC Drugs Our pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation. Infectious Disease Treatments Sterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases. Generic Drug Development We work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Related News & Insights

Speaking Engagement

October 12, 2022 3:00 PM - 4:00 PM PST

Obtaining and Enforcing Design Rights Against Virtual Infringement

Press Release

October 11, 2022

Sterne Kessler Notches Top Rankings in 2022 IPR Intelligence Report Based on PTAB Case Volume and Results

Sterne, Kessler, Goldstein & Fox

In the News

October 3, 2022

High Court Again Asks for SG’s Views on Patent Eligibility

Law360